Gyre Therapeutics, Inc. Common Stock
Symbol: GYRE (NASDAQ)
Company Description:
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
- Today's Open: $7.55
- Today's High: $7.735
- Today's Low: $7.461
- Today's Volume: 54.26K
- Yesterday Close: $7.58
- Yesterday High: $7.78
- Yesterday Low: $7.29
- Yesterday Volume: 74.38K
- Last Min Volume: 2
- Last Min High: $7.52
- Last Min Low: $7.52
- Last Min VWAP: $7.52
- Name: Gyre Therapeutics, Inc. Common Stock
- Website: https://www.gyretx.com
- Listed Date: 2023-10-31
- Location: SAN DIEGO, CA
- Market Status: Active
- CIK Number: 0001124105
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $688.47M
- Round Lot: 100
- Outstanding Shares: 90.83M
- Asset Type: CS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-10 | 8-K | View |
| 2025-08-26 | 4 | View |
| 2025-08-26 | 3 | View |
| 2025-08-22 | 8-K | View |
| 2025-08-11 | 10-Q | View |
| 2025-08-11 | 8-K | View |
| 2025-08-07 | 4 | View |
| 2025-06-06 | 4 | View |
| 2025-06-06 | 4 | View |
| 2025-06-06 | 4 | View |
| 2025-06-06 | 4 | View |
| 2025-06-06 | 4 | View |
| 2025-06-06 | 8-K | View |
| 2025-05-29 | 4 | View |
| 2025-05-28 | 4 | View |
| 2025-05-27 | 4 | View |
| 2025-05-23 | 8-K | View |
| 2025-05-23 | 424B5 | View |
| 2025-05-22 | 424B5 | View |
| 2025-05-22 | 8-K | View |